Clinical trial
Developing World Study for RotaTeq™ (V260-015)(COMPLETED)
NCT00362648 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00362648 |
|---|---|
| Title | Developing World Study for RotaTeq™ (V260-015)(COMPLETED) |
| Official title | Efficacy, Safety, and Immunogenicity of RotaTeq™ Among Infants in Asia and Africa |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vomiting, Diarrhea, Fever |
| Intervention type | Biological |
| Interventions | RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent, Comparator: Placebo |
| Enrollment | 7,504 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Aug 10, 2006 |
| Last update posted | Apr 13, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: